Bristol Myers Squibb Company (NYSE:BMY – Get Free Report) has received an average recommendation of “Hold” from the thirty brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, sixteen have assigned a hold recommendation, eleven have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $65.46.
Several research firms recently commented on BMY. Piper Sandler reduced their target price on shares of Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating on the stock in a report on Monday, October 26th. TD Cowen began coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “buy” rating for the company. Raymond James Financial initiated coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “strong-buy” rating for the company. Citigroup reiterated a “neutral” rating and issued a $70.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. Finally, Guggenheim reiterated a “buy” rating and issued a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st.
View Our Latest Stock Report on Bristol Myers Squibb
Trending Headlines about Bristol Myers Squibb
- Positive Sentiment: Bristol Myers will sponsor a Phase 1/2 study testing Erasca’s ERAS-0015 with BMS’s navlimetostat in patients with MTAP-deleted pancreatic cancer; Erasca will supply ERAS-0015. The partnership could advance a combination approach in a difficult-to-treat cancer, although it remains early-stage and no financial terms or clinical results were disclosed. Erasca clinical collaboration announcement
- Positive Sentiment: Barclays reaffirmed its Buy rating on BMY, indicating continued analyst confidence, though the report provided no new clinical or financial catalyst in the supplied details. Barclays rating report
- Neutral Sentiment: BMY was described as a trending stock, reflecting investor attention rather than a new business development or a clear explanation for its trading direction. BMY trending-stock report
Insider Buying and Selling at Bristol Myers Squibb
In other news, Director Julia A. Haller sold 3,800 shares of the company’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $63.31, for a total transaction of $240,578.00. Following the completion of the transaction, the director directly owned 30,279 shares of the company’s stock, valued at approximately $1,916,963.49. This represents a 11.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Phil M. Holzer sold 500 shares of the stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.05% of the stock is owned by insiders.
Institutional Investors Weigh In On Bristol Myers Squibb
Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. grew its position in shares of Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares during the period. State Street Corp increased its stake in shares of Bristol Myers Squibb by 7.3% during the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock worth $6,093,755,000 after purchasing an additional 7,192,724 shares in the last quarter. Primecap Management Co. CA purchased a new stake in shares of Bristol Myers Squibb during the second quarter worth about $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Bristol Myers Squibb by 0.5% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company’s stock worth $1,315,984,000 after purchasing an additional 119,690 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Bristol Myers Squibb by 2.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 18,762,589 shares of the biopharmaceutical company’s stock worth $1,137,847,000 after purchasing an additional 520,330 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.
Bristol Myers Squibb Stock Down 2.6%
Shares of BMY opened at $61.32 on Friday. Bristol Myers Squibb has a 1 year low of $45.26 and a 1 year high of $68.64. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44. The stock has a 50 day simple moving average of $61.75 and a two-hundred day simple moving average of $60.39. The firm has a market cap of $125.35 billion, a P/E ratio of 10.10, a P/E/G ratio of 0.32 and a beta of 0.20.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.10 by $0.25. The firm had revenue of $13.07 billion for the quarter, compared to the consensus estimate of $12.72 billion. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The business’s revenue was up 6.9% compared to the same quarter last year. During the same period last year, the firm posted $1.63 earnings per share. On average, analysts forecast that Bristol Myers Squibb will post 6.46 earnings per share for the current fiscal year.
Bristol Myers Squibb Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.1%. The ex-dividend date was Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.88%.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.
See Also
- Five stocks we like better than Bristol Myers Squibb
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
